Section
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as
The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surve
A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con
A multicenter study reveals that menstrual pain and abnormal uterine bleeding are highly prevalent in women with sickle cell disease and are linked to increased hospitalizations. Low awareness of hormonal therapies highlights a critical gap
This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target r
Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patien
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra
An international prospective validation confirms the PRESEV score reliably identifies adult sickle cell patients hospitalized for vaso-occlusive crisis (VOC) who are at low risk for acute chest syndrome (ACS), enabling safer outpatient mana
In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea
Use of systemic anticancer therapy in the last 30 days of life rose from 2015–2020, mainly due to immunotherapy; any SACT was linked to more than twofold higher odds of multiple ED visits, hospitalizations, ICU admission, and in-hospital de
A SEER–Medicare study of 315,089 older adults found that systemic anticancer therapy within 30 days of death—whether cytotoxic, targeted, immunotherapy, or combinations—was associated with substantially higher acute care use and lower hospi
In the phase II registration cohort of KOMET‑001, oral menin inhibitor ziftomenib achieved a CR/CRh rate of 22% (61% MRD negativity) and an ORR of 33% in relapsed/refractory NPM1‑mutated AML with manageable toxicity, supporting further stud
